Figure 2.

Introduction of A9(B8) enhanced the anticancer effect produced by EGFR-TKI application in NSCLC cells. MTT viability assays were performed to determine the change in IC₅₀ values of erlotinib/gefitinib in NCI-H1975 (A and B), NCI-H1650 (C and D), and A549 (E and F) cells after A9(B8) was introduced. Immunoblotting assays were performed to compare the differences in endogenous protein expression or phosphorylation among the three cell lines (G) with the performance of relative ratio within p-EGFR/EGFR (H) and ADAM17/tubulin (I) using semiquantitative analysis. MTT assays were performed with four duplicated wells for each sample. IC₅₀ data were calculated by using Prism Graph Pad 5.1 and presented as mean ± SD. Human plasma IgG was utilized as the control. Semiquantitative analysis of individual bands was performed using ImageJ. ∗P < .05 between compared groups. n.s. represents no significance between groups.